Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Besides being an invaluable marker of clonal disease in chronic myeloproliferative disorders (CMPDs), the JAK2 V617F mutation and the mutated allele burden have an impact on disease phenotype and may provide information on prognosis. Recently, hydroxyurea (HU) has been shown to induce a rapid decline in the JAK2 V617F allele burden. The aim of the present study was to assess the dynamics of the JAK2 V617F allele burden during long-term treatment with HU in a series of patients with CMPDs. The JAK2 V617F allele burden was determined by quantitative PCR in 24 patients of whom 17 received HU, four received anagrelide and three were followed without any cytoreductive therapy. During a median follow-up of 24.2 months, no significant reductions in the JAK2 V617F allele burden were seen in patients treated with HU. We conclude that HU has only a limited effect on the JAK2 V617F allele burden in CMPD.
Larsen
Thomas Stauffer
TS
Department of Hematology, Odense University Hospital, Odense, Denmark. thomas.stauffer.larsen@ouh.regionsyddanmark.dk
Pallisgaard
Niels
N
de Stricker
Karin
K
Møller
Michael Boe
MB
Hasselbalch
Hans Carl
HC
D000483:Alleles; D002908:Chronic Disease; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D009154:Mutation / Q000187:drug effects*; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D011799:Quinazolines / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; D053614:Janus Kinase 2; C021139:anagrelide; D006918:Hydroxyurea